Biosecure, Bruce Booth & ultrarare drugs: BioCentury’s latest podcast

Survey signals deep concern over anti-China bills. Takeaways from a talk with Atlas’ Booth. Winning approval in ultrarare diseases 

Bills seeking to rein in Chinese CDMOs and genomics companies will deal a massive blow to biotech companies, if passed in their current form, according to results from an industry survey conducted by BioCentury. On The latest BioCentury This Week podcast, BioCentury’s editors discuss results from the survey, including responses that underscore executives’ concerns that the legislation would cause delays in drug development and a majority’s displeasure with BIO’s about-face to support the measures.

The editors also assess whether the resignation of Rep. Mike Gallagher (R-Wis.), sponsor and champion of the House’s Biosecure Act, will slow the legislation and how the biopharma industry would like to modify the bills to reduce the harms they would inflict on drug developers. 

They also discuss takeaways from Editor in Chief Simone Fishburn’s conversation on The BioCentury Show with Atlas Venture’s Bruce Booth, and lessons from the Orchard Therapeutics unit of Kyowa Kirin Co. Ltd. (Tokyo:4151) on what it takes to get FDA’s approval for an ultrarare disease drug.   

For BioCentury’s complete coverage of the Biosecure Act and similar legislation in Senate, visit the Hot Topics page for the topic. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.